A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE)

被引：0
作者：
Matthew Gumbleton
Stephanie Allan
Hannah Conway
Kenneth Boucher
James Marvin
Josiah Hawks
William Burnett
Matthew Van Brocklin
Jonathan Whisenant
Glynn Gilcrease
Sumati Gupta
机构：
[1] University of Utah,Huntsman Cancer Institute
[2] University of Utah School of Medicine,Division of Oncology, Department of Internal Medicine
[3] University of Utah School of Medicine,Division of Epidemiology and Huntsman Cancer Institute, Department of Internal Medicine
[4] University of Utah,Flow Cytometry Core Facility, Health Science Center
[5] University of Utah School of Medicine,Department of Oncological Sciences
[6] University of Utah School of Medicine,Division of Oncology, Department of Surgery
[7] Department of Veterans Affairs Medical Center,undefined
来源：
BMC Research Notes | / 16卷
关键词：
APPEASE; Apatinib; Rivoceranib; Pembrolizumab; Immunotherapy; VEGF inhibition;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 132 条
[41]  
Lee JL(undefined)undefined undefined undefined undefined-undefined
[42]  
Fong L(undefined)undefined undefined undefined undefined-undefined
[43]  
Apte RS(undefined)undefined undefined undefined undefined-undefined
[44]  
Chen DS(undefined)undefined undefined undefined undefined-undefined
[45]  
Ferrara N(undefined)undefined undefined undefined undefined-undefined
[46]  
Motz GT(undefined)undefined undefined undefined undefined-undefined
[47]  
Santoro SP(undefined)undefined undefined undefined undefined-undefined
[48]  
Wang LP(undefined)undefined undefined undefined undefined-undefined
[49]  
Garrabrant T(undefined)undefined undefined undefined undefined-undefined
[50]  
Lastra RR(undefined)undefined undefined undefined undefined-undefined
12345678910